Company Vigil Neuroscience, Inc.

Equities

VIGL

US92673K1088

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 12:34:35 2024-03-28 pm EDT 5-day change 1st Jan Change
3.305 USD +3.28% Intraday chart for Vigil Neuroscience, Inc. +7.07% -3.70%

Business Summary

Vigil Neuroscience, Inc. is a clinical-stage biotechnology company. It is focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Its VGL101 product is a fully human monoclonal antibody TREM2 agonist that is being studied in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, a rare and fatal neurodegenerative disease. It is also conducting investigational new drug (IND)-enabling studies with a novel small molecule TREM2 agonist program to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations.

Number of employees: 69

Managers

Managers TitleAgeSince
Chief Executive Officer 55 20-06-30
Director of Finance/CFO 50 20-06-30
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer 50 23-02-26
Chief Operating Officer - 22-05-31
Chief Tech/Sci/R&D Officer - -
Investor Relations Contact - -
General Counsel - -
Comptroller/Controller/Auditor - -
Comptroller/Controller/Auditor - -

Members of the board

Members of the board TitleAgeSince
Chief Executive Officer 55 20-06-30
Director/Board Member 64 22-04-17
Director/Board Member 59 20-10-31
Director/Board Member 60 22-07-26
Chairman 49 20-05-31
Director/Board Member 39 21-07-31
Director/Board Member - 23-05-07
Director/Board Member 63 20-11-30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 36,929,035 32,434,798 ( 87.83 %) 0 87.83 %

Shareholders

NameEquities%Valuation
Atlas Venture Life Science Advisors LLC
16.27 %
5,836,874 16.27 % 20 M $
VV Manager LLC
13.98 %
5,015,929 13.98 % 17 M $
Northpond Ventures LLC
11.75 %
4,214,498 11.75 % 15 M $
AMGEN INC.
8.937 %
3,206,281 8.937 % 11 M $
Citadel Securities GP LLC
6.026 %
2,161,902 6.026 % 8 M $
BVF, Inc.
5.055 %
1,813,633 5.055 % 6 M $
Artal Group SA
5.048 %
1,811,191 5.048 % 6 M $
Deep Track Capital LP
4.446 %
1,594,931 4.446 % 6 M $
Hatteras Venture Partners
4.355 %
1,562,578 4.355 % 5 M $
Deerfield Management Co. LP (Private Equity)
3.271 %
1,173,523 3.271 % 4 M $

Company contact information

Vigil Neuroscience, Inc.

100 Forge Road Suite 700

02472, Watertown

+

http://www.vigilneuro.com
address Vigil Neuroscience, Inc.(VIGL)